Skip to content

London

Intelligent Automation

Breakthrough2024 is the must-attend event for life sciences leaders across the globe. It’s the one place where leaders like you engage in the brightest, forward-looking life sciences industry conversations and hear the latest LifeSphere announcements.

Bringing together industry experts, pharmaceutical leaders, and regulatory authorities, Breakthrough2024 will explore the transformation of intelligent automation - from the benefits being delivered via out-of-the-box solutions, to the value customers are realizing with automation, Generative AI, large language models, and real-world data. 

Navigating these extraordinary shifts requires new thinking. Join us as we examine the promise, the reality, and the implications for life science organizations leveraging next-gen technologies to solve critical business challenges across the R&D ecosystem.

Reasons to Attend

  • Explore the latest innovations transforming our industry
  • Build your professional brand with industry colleagues
  • Engage with partners and experts at the Innovation Center
  • Get up to speed on topics that matter to you and our industry

Register Here

Grab your spot now and see the full agenda!

Please view our Privacy Policy for information on how ArisGlobal handles customer data.

Discussions you won’t want to miss

  • Streamlining R&D IT and scaling operations with the help of automation; plus, practical use cases for Generative AI and LLM technologies.
  • Integrating Safety & Regulatory processes via automation
  • Moving Pharmacovigilance and Regulatory operations in the cloud: stories from top pharma on their process, challenges, and victories.
  • Leveraging proprietary + real-world data to remain competitive and innovative.
  • What to expect in 2024 Regulatory Operations, with Steve Gens (Gens & Associates).

...and three major product announcements from ArisGlobal for 2024 and beyond.

Speakers that inspire

  • Industry Experts who will share their perspective on Pharma Digitization & other related topics
  • ArisGlobal Clients who are seeing the benefits,
  • Regulatory authorities that are leading the way, and
  • Partners which are not only helping to implement solutions but also enhancing the value of connected cloud-based data by enabling greater interoperability with third-party assets and innovation.

Speaker Highlight

Anand Ananthakrishnan

Senior Director of Drug Safety and Pharmacovigilance at Blueprint Medicines

With over 20 years of experience in the pharmacovigilance domain, Anand Ananthakrishnan currently holds the position of Senior Director of Drug Safety and Pharmacovigilance at Blueprint Medicines, a biotechnology firm located in Cambridge, Massachusetts. Before joining Blueprint Medicines, he served as the Director of PV Safety Systems and Operations at Fresenius Medical Care North America and as the Associate Director of Safety Systems at Vertex Pharmaceuticals. An advocate for the use of technology in pharmacovigilance, Anand has been at the forefront of implementing cutting-edge systems to enhance efficiency across all aspects of the field. He strongly emphasizes the importance of an integrated ecosystem for seamless information flow between case processing, signal detection, literature search, and submission systems. Anand was honored with the “All Star Award” for Innovation at the Breakthrough 2022 conference held in Boston in Oct 2022. He was also a speaker on practical implementation of AI in PV at the WDSC held in Boston in Oct 2023.

Anand Ananthakrishnan

Senior Director of Drug Safety and Pharmacovigilance at Blueprint Medicines

With over 20 years of experience in the pharmacovigilance domain, Anand Ananthakrishnan currently holds the position of Senior Director of Drug Safety and Pharmacovigilance at Blueprint Medicines, a biotechnology firm located in Cambridge, Massachusetts. Before joining Blueprint Medicines, he served as the Director of PV Safety Systems and Operations at Fresenius Medical Care North America and as the Associate Director of Safety Systems at Vertex Pharmaceuticals. An advocate for the use of technology in pharmacovigilance, Anand has been at the forefront of implementing cutting-edge systems to enhance efficiency across all aspects of the field. He strongly emphasizes the importance of an integrated ecosystem for seamless information flow between case processing, signal detection, literature search, and submission systems. Anand was honored with the “All Star Award” for Innovation at the Breakthrough 2022 conference held in Boston in Oct 2022. He was also a speaker on practical implementation of AI in PV at the WDSC held in Boston in Oct 2023.

Hans van Leeuwen

Head of RA Data & Systems Excellence at Astellas

Hans van Leeuwen has over 20 years of experience in Regulatory Operations. He has managed global regulatory operations groups with responsibilities including regulatory information management, submission management, labeling, regulatory planning, change control and regulatory intelligence. On the IT side his experience includes global responsibility for (pre-) clinical, regulatory and pharmacovigilance systems such as clinical trial management, document management and adverse event reporting systems.
Hans has a strong interest in the use of data standards in regulatory submissions and has served on multiple representative committees promoting the use of standards in regulatory.
His previous employers include Organon Biosciences, Schering-Plough and MSD and he is currently at Astellas as head of RA Data & Systems Excellence. Prior to working in regulatory, Hans held management and research positions in multiple disciplines including analytical chemistry, statistics and data analysis. Hans holds a Ph.D. in Chemistry.

Hans van Leeuwen

Head of RA Data & Systems Excellence at Astellas

Hans van Leeuwen has over 20 years of experience in Regulatory Operations. He has managed global regulatory operations groups with responsibilities including regulatory information management, submission management, labeling, regulatory planning, change control and regulatory intelligence. On the IT side his experience includes global responsibility for (pre-) clinical, regulatory and pharmacovigilance systems such as clinical trial management, document management and adverse event reporting systems.
Hans has a strong interest in the use of data standards in regulatory submissions and has served on multiple representative committees promoting the use of standards in regulatory.
His previous employers include Organon Biosciences, Schering-Plough and MSD and he is currently at Astellas as head of RA Data & Systems Excellence. Prior to working in regulatory, Hans held management and research positions in multiple disciplines including analytical chemistry, statistics and data analysis. Hans holds a Ph.D. in Chemistry.

Claudia Lehmann

Vice President of Global Patient Safety and Pharmacovigilance Operations & Systems for Boehringer Ingelheim

Claudia Lehmann serves as Vice President of Global Patient Safety and Pharmacovigilance Operations & Systems for Boehringer Ingelheim. Her passion lies in patient safety, process design and efficiency and breaking down complex situations into manageable pieces that can be addressed in an agile and comprehensible way, never losing sight of the overall purpose of the task and the big picture. Prior to this role, she was leading Biostatistics and Data Management Europe within Boehringer Ingelheim.
Claudia has been trained in medical information management at an affiliation of the University of Ulm, Germany.

Claudia Lehmann

Vice President of Global Patient Safety and Pharmacovigilance Operations & Systems for Boehringer Ingelheim

Claudia Lehmann serves as Vice President of Global Patient Safety and Pharmacovigilance Operations & Systems for Boehringer Ingelheim. Her passion lies in patient safety, process design and efficiency and breaking down complex situations into manageable pieces that can be addressed in an agile and comprehensible way, never losing sight of the overall purpose of the task and the big picture. Prior to this role, she was leading Biostatistics and Data Management Europe within Boehringer Ingelheim.
Claudia has been trained in medical information management at an affiliation of the University of Ulm, Germany.

Franziska Rathjens

DQP for Pharmacovigilance and DL Safety Officer at B. Braun Melsungen AG

Dr. Franziska Rathjens is a pharmacist and holds a Master’s and doctoral degree in Molecular Medicine. She joined B. Braun Melsungen AG in 2019 as a Deputy Qualified Person for Pharmacovigilance and Deputy Local Safety Officer for Germany.
After initiating and managing the establishment of new and improvement of existing processes from 2020 to 2022 within B. Braun’s Global Pharmacovigilance & Patient Safety Department, she built and now leads a team responsible for Business Process Management & Pharmacovigilance Tools. This team is in charge of the applications used in pharmacovigilance at B. Braun, especially of the pharmacovigilance database Lifesphere Multivigilance. In close collaboration with the teams responsible for case processing, periodic safety reporting and signal management automations have and are being implemented to bring value to the business users.

Franziska Rathjens

DQP for Pharmacovigilance and DL Safety Officer at B. Braun Melsungen AG

Dr. Franziska Rathjens is a pharmacist and holds a Master’s and doctoral degree in Molecular Medicine. She joined B. Braun Melsungen AG in 2019 as a Deputy Qualified Person for Pharmacovigilance and Deputy Local Safety Officer for Germany.
After initiating and managing the establishment of new and improvement of existing processes from 2020 to 2022 within B. Braun’s Global Pharmacovigilance & Patient Safety Department, she built and now leads a team responsible for Business Process Management & Pharmacovigilance Tools. This team is in charge of the applications used in pharmacovigilance at B. Braun, especially of the pharmacovigilance database Lifesphere Multivigilance. In close collaboration with the teams responsible for case processing, periodic safety reporting and signal management automations have and are being implemented to bring value to the business users.

Andrea Rogers

Head of Digital, Technology, and Innovation (DTI) teams at Amgen

Andrea Rogers leads the Digital, Technology, and Innovation (DTI) teams who provide technology solutions for Amgen’s Global Patient Safety, Global Development, and Global Medical organizations. Andrea has spent more than 30 years working in Information Technology supporting Healthcare, first working for payers within the US, and for the last 17+ years at Amgen.
During her tenure at Amgen, Andrea has held numerous roles of increasing scope and responsibility, including in Enterprise Technology groups focused on data and analytics, and for the past eight years in the R&D Informatics organization. In addition to her current role supporting Patient Safety, Development, and Medical, Andrea has also led the teams supporting Commercialization and Business Development. Andrea is the R&D technology integration lead for Amgen’s acquisition of Horizon Therapeutics and in 2024 will lead an effort to transform the technology ecosystem for Global Patient Safety. Andrea holds a Bachelor of Arts degree from UC Santa Cruz, and a Master of Arts from UC Davis.

Andrea Rogers

Head of Digital, Technology, and Innovation (DTI) teams at Amgen

Andrea Rogers leads the Digital, Technology, and Innovation (DTI) teams who provide technology solutions for Amgen’s Global Patient Safety, Global Development, and Global Medical organizations. Andrea has spent more than 30 years working in Information Technology supporting Healthcare, first working for payers within the US, and for the last 17+ years at Amgen.
During her tenure at Amgen, Andrea has held numerous roles of increasing scope and responsibility, including in Enterprise Technology groups focused on data and analytics, and for the past eight years in the R&D Informatics organization. In addition to her current role supporting Patient Safety, Development, and Medical, Andrea has also led the teams supporting Commercialization and Business Development. Andrea is the R&D technology integration lead for Amgen’s acquisition of Horizon Therapeutics and in 2024 will lead an effort to transform the technology ecosystem for Global Patient Safety. Andrea holds a Bachelor of Arts degree from UC Santa Cruz, and a Master of Arts from UC Davis.

Marina Suvakov

Global Head, Product Safety Surveillance at PMI Life Sciences

Marina is a passionate, experienced, and motivated professional with over 13 years of experience in the pharmaceutical industry, particularly safety surveillance. Her expertise and experience in pharmacovigilance and quality activities, combined with her innovative thinking style and enthusiasm has helped many companies and departments propel through their transformation journeys. Her expertise are in process optimization and ensuring standards and compliance within the GVP guidelines. Marina holds a master’s degree in pharmaceutical sciences from Greenwich University and a bachelor’s degree in medical biochemistry from Brunel University.

Marina Suvakov

Global Head, Product Safety Surveillance at PMI Life Sciences

Marina is a passionate, experienced, and motivated professional with over 13 years of experience in the pharmaceutical industry, particularly safety surveillance. Her expertise and experience in pharmacovigilance and quality activities, combined with her innovative thinking style and enthusiasm has helped many companies and departments propel through their transformation journeys. Her expertise are in process optimization and ensuring standards and compliance within the GVP guidelines. Marina holds a master’s degree in pharmaceutical sciences from Greenwich University and a bachelor’s degree in medical biochemistry from Brunel University.

Featuring speakers and attendees from:

About

ArisGlobal’s annual Breakthrough is a one-of-a-kind event that brings together key leaders of the life sciences to provide unique insights around the innovation, processes, talent and technology to drive greater efficiency, strategy and results for businesses. Breakthrough2024 will feature sessions and keynotes by leading voices from across the industry, aimed at sharing ideas, experiences and best practices. You will also have the opportunity to visit the Innovation Center where live demonstrations across the LifeSphere platform will be available, plus time to network with ArisGlobal’s preferred partners as part of our open ecosystem.

Travel & Info

Venue

We are excited to bring Breakthrough2024 to London, England on March 19-20, 2024.

Leonardo Royal London St Paul’s
10 Godliman St
London - EC4V 5AJ

More Travel Info Breakthrough2024 FAQs

Hear from past attendees

“This is a great opportunity to connect and build a bigger partnership with life sciences peers and regulators”

“A tremendous event to learn from industry thought leaders and move life sciences forward”

Breakthrough2024 Sponsors

ArisGlobal Launches LifeSphere NavaX™   Learn More

Join us at Breakthrough 2024 to explore life sciences transformation through Intelligent Automation

Register Here